CORNELIUS JOSEPH CLANCY
Medical Practice in Pittsburgh, PA
License number
Pennsylvania MD442082
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Pittsburgh, PA 15203
Personal information
See more information about CORNELIUS JOSEPH CLANCY at radaris.comName
Address
Phone
910 Bingham St APT J, Pittsburgh, PA 15203
Professional information
Cornelius Clancy, Pittsburgh PA
Work:
University of Pittsburgh
3601 5Th Ave, Pittsburgh, PA 15213
3601 5Th Ave, Pittsburgh, PA 15213
Dr. Cornelius J Clancy, Pittsburgh PA - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
3601 5Th Ave SUITE 700, Pittsburgh 15213
(412) 647-0996 (Phone), (412) 647-3162 (Fax)
1600 SW Archer Rd SUITE R2, Gainesville 32610
(352) 265-0606 (Phone), (352) 379-4015 (Fax)
UNIVERSITY OF PITTSBURGH INFECTIOUS DISEASES CLINIC
3601 5Th Ave SUITE 7TH, Pittsburgh 15213
(412) 647-0996 (Phone)
(412) 647-0996 (Phone), (412) 647-3162 (Fax)
1600 SW Archer Rd SUITE R2, Gainesville 32610
(352) 265-0606 (Phone), (352) 379-4015 (Fax)
UNIVERSITY OF PITTSBURGH INFECTIOUS DISEASES CLINIC
3601 5Th Ave SUITE 7TH, Pittsburgh 15213
(412) 647-0996 (Phone)
Certifications:
Internal Medicine, 2003
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Washington Center / School of Medicine
Graduated: 1991
Washington Center / School of Medicine
Graduated: 1991
Polynucleotides And Polypeptides Identified By Iviat Screening And Methods Of Use
US Patent:
2010011, May 13, 2010
Filed:
Mar 7, 2008
Appl. No.:
12/529919
Inventors:
Cornelius Joseph Clancy - Pittsburgh PA, US
Shaoji Cheng - Gainesville FL, US
Shaoji Cheng - Gainesville FL, US
International Classification:
A61K 39/00, C40B 40/10, C07K 14/00, C07K 7/00, C40B 40/06, C07H 21/04, C40B 30/04, C07K 16/00, C12Q 1/68
US Classification:
4241851, 506 18, 530350, 530300, 506 16, 536 231, 506 9, 5303879, 435 6
Abstract:
The and polypeptides of the invention have been found to be immunogenic and are useful as diagnostic test antigens. The polypeptide antigens of the subject invention can provide the basis of a diagnostic assay that would allow the rapid, in-house, laboratory diagnosis of infection with and/or using a sample (e.g., serum, plasma, or whole blood) from an infected human or animal. Additionally, the subject invention provides methods of detecting the presence of and/or in biological or environmental samples utilizing antibodies provided by the subject invention. Furthermore, the use of single antigens or, more preferably, one or more groups (sets) of antigens of the invention in the diagnosis of these important diseases offers many advantages including enhanced test specificity, ease of testing and consistency of results using synthetically or recombinantly produced test antigens instead of cultured, whole organisms. In one embodiment, the group of antigens comprises or consists of one or more polypeptides (e.g., one, two, three, or four or more antigens) selected from among SET1 (chromatin regulatory protein), ENO1 (enolase I), PGK1-2 (phosphoglycerate kinease), and MUC1-2 (cell surface glycoprotein). In another embodiment, the group of antigens comprises or consists of one or more polypeptides (e.g., one, two, three, four, five, six, or seven or more polypeptides) selected from among SET1, ENO1, FBA1, PGK1-1, PGK1-2, MUC1-2, and BGL2. In another embodiment, the group of antigens comprises or consists of one or more polypeptides (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or fifteen or more polypeptides) selected from among MET6-1, MET6-2, NOT5, RBT4, IPF9162, CAR1, GAP1, SET1, ENO1, FBA1, PGK1-1, PGK1-2, MUC1-1, MUC1-2, and BGL2.